<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2486134-B1" country="EP" doc-number="2486134" kind="B1" date="20140108" family-id="43857117" file-reference-id="315057" date-produced="20180825" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146587880" ucid="EP-2486134-B1"><document-id><country>EP</country><doc-number>2486134</doc-number><kind>B1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-10822611-A" is-representative="NO"><document-id mxw-id="PAPP154850072" load-source="docdb" format="epo"><country>EP</country><doc-number>10822611</doc-number><kind>A</kind><date>20101006</date><lang>EN</lang></document-id><document-id mxw-id="PAPP183607706" load-source="docdb" format="original"><country>EP</country><doc-number>10822611.9</doc-number><date>20101006</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140552685" ucid="US-2010051646-W" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>2010051646</doc-number><kind>W</kind><date>20101006</date></document-id></priority-claim><priority-claim mxw-id="PPC140551194" ucid="US-24925309-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>24925309</doc-number><kind>P</kind><date>20091006</date></document-id></priority-claim><priority-claim mxw-id="PPC140552428" ucid="US-24959609-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>24959609</doc-number><kind>P</kind><date>20091007</date></document-id></priority-claim></priority-claims><dates-of-public-availability><intention-to-grant-date><date>20130813</date></intention-to-grant-date><search-report-dispatch-date><date>20130110</date></search-report-dispatch-date></dates-of-public-availability><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1989324159" load-source="docdb">A61P  35/00        20060101ALI20130104BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989324160" load-source="docdb">A61K  38/17        20060101ALI20130104BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989324161" load-source="docdb">C12N  15/63        20060101AFI20130104BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989324162" load-source="docdb">A61K  38/16        20060101ALI20130104BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989324163" load-source="docdb">A61P  31/04        20060101ALI20130104BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1991055529" load-source="docdb" scheme="CPC">C12N2799/021       20130101 LA20151212BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1991057756" load-source="docdb" scheme="CPC">C12N  15/85        20130101 LA20151212BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1991058438" load-source="docdb" scheme="CPC">A61K  39/0011      20130101 LA20151212BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1991058710" load-source="docdb" scheme="CPC">C12N  15/86        20130101 LA20151212BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1991062455" load-source="docdb" scheme="CPC">C12N  15/79        20130101 LA20151212BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2020471544" load-source="docdb" scheme="CPC">A61K  38/18        20130101 LI20150925BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2020472384" load-source="docdb" scheme="CPC">C12N2830/20        20130101 LA20150925BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2020473291" load-source="docdb" scheme="CPC">C12N  15/63        20130101 LA20150924BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2020474228" load-source="docdb" scheme="CPC">C07K  14/705       20130101 LI20150925BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2020476597" load-source="docdb" scheme="CPC">A61K  38/2257      20130101 LI20150925BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2020476694" load-source="docdb" scheme="CPC">A61K  38/164       20130101 LI20150925BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2020478434" load-source="docdb" scheme="CPC">A61K  31/59        20130101 FI20150925BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2020478445" load-source="docdb" scheme="CPC">A61K  48/005       20130101 LI20150925BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2020478795" load-source="docdb" scheme="CPC">A61K  38/177       20130101 LI20150925BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2020478879" load-source="docdb" scheme="CPC">A61K  38/27        20130101 LI20150925BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132368273" lang="DE" load-source="patent-office">VERWENDUNG EINES TOLL-LIKE-REZEPTORS UND SEINES AGONISTEN ZUR KREBSBEHANDLUNG</invention-title><invention-title mxw-id="PT132368274" lang="EN" load-source="patent-office">USE OF TOLL-LIKE RECEPTOR AND AGONIST FOR TREATING CANCER</invention-title><invention-title mxw-id="PT132368275" lang="FR" load-source="patent-office">UTILISATION DE RÉCEPTEUR DE TYPE TOLL ET AGONISTE POUR LE TRAITEMENT DU CANCER</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR919533813" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>PANACELA LABS INC</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR919525472" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>PANACELA LABS, INC.</last-name></addressbook></applicant><applicant mxw-id="PPAR919535151" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>ROSWELL PARK CANCER INST</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR919511517" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>ROSWELL PARK CANCER INSTITUTE</last-name></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919515646" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>GUDKOV ANDREI V</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919507549" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>GUDKOV, ANDREI, V.</last-name></addressbook></inventor><inventor mxw-id="PPAR919020483" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>GUDKOV, ANDREI, V.</last-name><address><street>1933 Sweet Road</street><city>East Aurora, NY 14052</city><country>US</country></address></addressbook></inventor></inventors><assignees><assignee mxw-id="PPAR919020486" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Panacela Labs, Inc.</last-name><iid>101307805</iid><address><street>73 High Street</street><city>Buffalo, NY 14203</city><country>US</country></address></addressbook></assignee><assignee mxw-id="PPAR919020484" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>Roswell Park Cancer Institute</last-name><iid>100210657</iid><address><street>Elm and Carlton Streets</street><city>Buffalo, NY 14263</city><country>US</country></address></addressbook></assignee></assignees><agents><agent mxw-id="PPAR919020485" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Zacco Denmark A/S</last-name><iid>101287454</iid><address><street>Hans Bekkevolds Allé 7</street><city>2900 Hellerup</city><country>DK</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="US-2010051646-W"><document-id><country>US</country><doc-number>2010051646</doc-number><kind>W</kind><date>20101006</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2011044246-A1"><document-id><country>WO</country><doc-number>2011044246</doc-number><kind>A1</kind><date>20110414</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS549921679" load-source="docdb">AL</country><country mxw-id="DS549779511" load-source="docdb">AT</country><country mxw-id="DS549921681" load-source="docdb">BE</country><country mxw-id="DS549886307" load-source="docdb">BG</country><country mxw-id="DS549863121" load-source="docdb">CH</country><country mxw-id="DS549779002" load-source="docdb">CY</country><country mxw-id="DS549779512" load-source="docdb">CZ</country><country mxw-id="DS549921682" load-source="docdb">DE</country><country mxw-id="DS549779003" load-source="docdb">DK</country><country mxw-id="DS549779004" load-source="docdb">EE</country><country mxw-id="DS549864845" load-source="docdb">ES</country><country mxw-id="DS549886308" load-source="docdb">FI</country><country mxw-id="DS549886309" load-source="docdb">FR</country><country mxw-id="DS549921683" load-source="docdb">GB</country><country mxw-id="DS549779013" load-source="docdb">GR</country><country mxw-id="DS549921684" load-source="docdb">HR</country><country mxw-id="DS549779525" load-source="docdb">HU</country><country mxw-id="DS549863134" load-source="docdb">IE</country><country mxw-id="DS549921685" load-source="docdb">IS</country><country mxw-id="DS549886318" load-source="docdb">IT</country><country mxw-id="DS549779014" load-source="docdb">LI</country><country mxw-id="DS549794872" load-source="docdb">LT</country><country mxw-id="DS549779526" load-source="docdb">LU</country><country mxw-id="DS549794885" load-source="docdb">LV</country><country mxw-id="DS549794886" load-source="docdb">MC</country><country mxw-id="DS549867220" load-source="docdb">MK</country><country mxw-id="DS549867221" load-source="docdb">MT</country><country mxw-id="DS549886319" load-source="docdb">NL</country><country mxw-id="DS549864854" load-source="docdb">NO</country><country mxw-id="DS549886320" load-source="docdb">PL</country><country mxw-id="DS549867226" load-source="docdb">PT</country><country mxw-id="DS549886321" load-source="docdb">RO</country><country mxw-id="DS549867227" load-source="docdb">RS</country><country mxw-id="DS549886326" load-source="docdb">SE</country><country mxw-id="DS549867228" load-source="docdb">SI</country><country mxw-id="DS549863135" load-source="docdb">SK</country><country mxw-id="DS549863136" load-source="docdb">SM</country><country mxw-id="DS549794888" load-source="docdb">TR</country></ep-contracting-states><ep-extended-states><ep-extended-state-data><country>BA</country></ep-extended-state-data><ep-extended-state-data><country>ME</country></ep-extended-state-data></ep-extended-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><description mxw-id="PDES63960314" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001"><b>FIELD OF THE INVENTION</b></heading><p id="p0001" num="0001">This invention relates to methods of treating cancer and infectious diseases.</p><heading id="h0002"><b>BACKGROUND OF THE INVENTION</b></heading><p id="p0002" num="0002">Toll-like receptors are responsible for the recognition of most common patterns of bacterial and viral pathogens. Their activation results in recruitment of innate and subsequently adaptive immune response. Receptor cells of the immune system to the site of presence of antigens is the key step in effective immune response. That is why immunization involves the use of different types of adjuvants. Although the majority of tumors express tumor-specific antigens, they are using a number of mechanisms allowing then to escape immune recognition. It was recently demonstrated in mouse models that activation of TLR5 by its ligand and agonist, bacterial flagellin, results in the induction of antitumor effect against those tumors that express functional TLR5. This opens a general opportunity for considering TLR5 agonists for cancer immunotherapy. There are two major obstacles on the way to reduction of this idea to practice. First, is the rare incidence of tumors expressing functional TLR5 limiting applicability of this approach to only a small subset of tumors. Second, systemic administration of TLR5 agonist leads to activation of TRL5 signaling in all cells that have functional receptor making response unfocused and not tumor-specific. Accordingly, there is a need in the art for a mechanism or method for autocrine activation of TLR receptor signaling in infected or tumor cells with minimal systemic effect thus enabling to attract innate immune response specifically to the infected cell or tumor.</p><heading id="h0003"><b>SUMMARY OF THE INVENTION</b></heading><p id="p0003" num="0003">The present invention may be directed to a vector comprising a first and second nucleic acid, wherein the first nucleic acid encodes a toll-like receptor and the second nucleic acid encodes a toll-like receptor agonist. The first nucleic acid may encode for a secreted form of a toll-like receptor. The second nucleic acid may be a secreted form of flagellin. The toll-like receptor agonist may be flagellin. The vector may be a mammalian expression vector. The<!-- EPO <DP n="2"> --> vector may be expressed from an adenovirus, a lentivirus or a liposome. The secreted form of flagellin may be CBLB502S. The toll-like receptor may be TLR-5.</p><p id="p0004" num="0004">The present invention may be used for treating cancer in a mammal comprising administering to a mammal in need thereof a agent comprising the vector comprising a first and second nucleic acid, wherein the first nucleic acid encodes a toll-like receptor and the second nucleic acid encodes a toll-like receptor agonist. The cancer may be a tumor. The tumor may be derived from the group consisting of prostate, breast, colon, esophagus, stomach, lung, pancreatic, renal, thyroid, ovaries, throat, or the cervix. The tumor may be derived from the group consisting of sarcomas, melenomas, leukemias, and lymphomas. The agent may be administered in trans or outside from the tumor of the mammal. The agent may be administered directly into a tumor of the mammal. The agent may be administered in combination with an immunostimulant. The immunostimulant may be selected from the group consisting of growth hormone, prolactin and vitamin D. The growth hormone may be somatotrophin. The agent may be administered in combination with a cytokine. The cytokine may be a stem cell factor.</p><p id="p0005" num="0005">The present invention can also be used for treating an infection in a mammal comprising administering to a mammal in need thereof the agent of agent comprising the vector comprising a first and second nucleic acid, wherein the first nucleic acid encodes a toll-like receptor and the second nucleic acid encodes a toll-like receptor agonist. The cancer may be a tumor. The infection may be derived from the group consisting of viruses, bacteria, protozoan parasites and fungi.</p><heading id="h0004"><b>BRIEF DESCRIPTION OF THE DRAWINGS</b></heading><p id="p0006" num="0006"><ul><li><figref idrefs="f0001 f0002 f0003">Figure 1A-1C</figref> depicts schematic maps of adenoviral vectors expressing TLR5, CBLB502S and their combination (TLR5 + CBLB502S).</li><li><figref idrefs="f0004">Figure 2</figref> depicts the results of the ratio of tumor volume in mice over a number of days in tumor cells (A549) transduced with a control vector (without TLR5) or vector expressing TLR5 wherein the mice are treated three days with either CBLB502 or PBS.</li><li><figref idrefs="f0005">Figure 3</figref> depicts suppression of tumor growth by injection of adenovirus comprising vector coexpressing CBLB502S and Toll-like receptor wherein the adenovirus is injected into syngeneic mice CT26 colon carcinoma tumor and studying the in-cis and in-trans effects of the adenoviral vector constructs.<!-- EPO <DP n="3"> --></li><li><figref idrefs="f0006">Figure 4</figref> shows the domain structure of bacterial flagellin. The Ca backbone trace, hydrophobic core distribution and structural information of F41. Four distinct hydrophobic cores that define domains D1, D2a, D2b and D3. All the hydrophobic side-chain atoms are displayed with the Ca backbone. Side-chain atoms are color coded: Ala, yellow; Leu, Ile or Val, orange; Phe and Tyr, purple (carbon atoms) and red (oxygen atoms). c, Position and region of various structural features in the amino-acid sequence of flagellin. Shown are, from top to bottom: the F41 fragment in blue; three b-folium folds in brown; the secondary structure distribution with a-helix in yellow, b-structure in green, and b-turn in purple; tic mark at every 50th residue in blue; domains D0, D1, D2 and D3; the axial subunit contact region within the proto-element in cyan; the well-conserved amino-acid sequence in red and variable region in violet; point mutations in F41 that produce the elements of different supercoils. Letters at the bottom indicate the morphology of mutant elements: L (D107E, R124A, R124S, G426A), L-type straight; R (A449V), R-type straight; C (D313Y, A414V, A427V, N433D), curly33.</li><li><figref idrefs="f0007">Figure 5</figref> shows a schematic of Salmonella flagellin domains, its fragments, and its interaction with TLR5. Dark bars denote regions of the flagellin gene used to construct fragments comprising A, B, C, A' and B'.</li><li><figref idrefs="f0008">Figure 6</figref> depicts flagellin derivatives. The domain structure and approximate boundaries (amino acid coordinates) of selected flagellin derivatives (listed on the right). FliC flagellin of Salmonella dublin is encoded within 505 amino acids (aa).</li><li><figref idrefs="f0009 f0010 f0011 f0012 f0013 f0014 f0015 f0016 f0017 f0018">Figure 7</figref> shows the nucleotide and amino acid sequence for the following flagellin variants: AA' (SEQ ID NO: 7-8), AB' (SEQ ID NO: 9-10), BA' (SEQ ID NO: 11-12), BB' (SEQ ID NO: 13-14), CA' (SEQ ID NO: 15-16), CB' (SEQ ID NO: 17-18), A (SEQ ID NO: 19-20), B (SEQ ID NO: 21-22), C (SEQ ID NO: 23-24), GST-A' (SEQ ID NO: 25-26), GST-B' (SEQ ID NO: 27-28), AA'n1-170 (SEQ ID NO: 29-30), AA'n1-163 (SEQ ID NO: 33-34), AA'n54-170 (SEQ ID NO: 31-32), AA'n54-163 (SEQ ID NO: 335-36), AB'nl-170 (SEQ ID NO: 37-38), AB'n1-163 (SEQ ID NO: 39-40), AA'n1-129 (SEQ ID NO: 41-42), AA'n54-129 (SEQ ID NO: 43-44), AB'n1-129 (SEQ ID NO: 45-46), AB'n54-129 (SEQ ID NO: 47-48), AA'n1-100 (SEQ ID NO: 49-50), AB'n1-100 (SEQ ID NO: 51-52), AA'n1-70 (SEQ ID NO: 53-54) and AB'n1-70 (SEQ ID NO: 55-56). The pRSETb leader sequence is shown in Italic (leader includes Met, which is also amino acid 1 of FliC). The N terminal constant domain is underlined.<!-- EPO <DP n="4"> --> The amino acid linker sequence is in Bold. The C terminal constant domain is underlined. GST, if present, is highlighted.</li><li><figref idrefs="f0020 f0021 f0022">Figure 8</figref> shows a comparison of amino acid sequences of the conserved amino (<figref idrefs="f0020 f0021">Fig. 8A</figref>) and carboxy (<figref idrefs="f0022">Fig. 8B</figref>) terminus from 21 species of bacteria. The 13 conserved amino acids important for TLR5 activity are shown with shading. The amino acid sequences are identified by their accession numbers from TrEMBL (first letter = Q) or Swiss-Prot (first letter = P).</li><li><figref idrefs="f0023">Figure 9</figref> shows the nucleic acid and amino acid sequence for the human Toll-like receptor 5 protein.</li></ul></p><heading id="h0005"><b>DETAILED DESCRIPTION</b></heading><p id="p0007" num="0007">The inventors have made the surprising discovery that the provision of a toll-like receptor, such as toll-like receptor 5 (TLR-5), in combination with a toll-like receptor agonist, such as flagellin, results in a cis and in-trans effect that recruits cells involved in both the innate (cis effect) and adaptive (trans effect) immune response to specifically kill cancer cells and cells infected with a pathogen via the NF-κB apoptosis pathway. While not being bound by theory, the idea implemented in this invention was to (i) overcome the dependence of TLR-mediated immunization strategies on pre-existing TLR expression in a tumor by transducing the tumor with a construct driving expression of TLR; and (ii) to direct the immune response to the tumor by creating local pool of TLR agonist. For example, drug formulations comprising TLR simultaneously induce expression and activate TLR, thereby exposing tumor cells to the host immune system imitating the situation of massive bacterial penetration through the intestinal wall.</p><p id="p0008" num="0008">By providing a TLR such as TLR5, and a TLR agonist such as flagellin, to interact and activate both the innate and adaptive immune system, the method can be used to treat tumors derived from the prostate, breast, colon, esophagus, stomach, lung, pancreatic, renal, thyroid, ovaries, throat, or the cervix cancer as well as treating sarcomas, melenomas, leukemias, and lymphomas. Applications of this method are not limited to cancer treatments, as this method can also be used to treat infections derived from viruses, bacteria, protozoan parasites and fungi.</p><p id="p0009" num="0009">Variations of providing the TLR and TLR agonist may include vectors, co-expressing the TLR receptor and a secretable form of flagellin that activates TLR activity in the same compromised mammalian cell. The method of the present invention may also include vector<!-- EPO <DP n="5"> --> constructs that express the TLR receptor in a mammalian cell and the TLR agonist being administered in trans to the cell. For example, an adenoviral vector may require modification of flagellin to reach its effective synthesis and secretion by mammalian cells.</p><heading id="h0006"><b>1. Definitions.</b></heading><p id="p0010" num="0010">The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. As used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise.</p><p id="p0011" num="0011">For recitation of numeric ranges herein, each intervening number there between with the same degree of precision is explicitly contemplated. For example, for the range of 6-9, the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0-7.0, the numbers 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6,9, and 7.0 are explicitly contemplated.</p><p id="p0012" num="0012">"Administer" may mean a single dose or multiple doses of an agent or agent.</p><p id="p0013" num="0013">"Analog" may mean, in the context of a peptide or polypeptide, a peptide or polypeptide comprising one or more non-standard amino acids or other structural variations from the conventional set of amino acids.</p><p id="p0014" num="0014">"Antibody" may mean an antibody of classes IgG, IgM, IgA, IgD or IgE, or fragments, or derivatives thereof, including Fab, F(ab')2, Fd, and single chain antibodies, diabodies, bispecific antibodies, bifunctional antibodies and derivatives thereof. The antibody may be a monoclonal antibody, polyclonal antibody, affinity purified antibody, or mixtures thereof which exhibits sufficient binding specificity to a desired epitope or a sequence derived therefrom. The antibody may also be a chimeric antibody. The antibody may be derivatized by the attachment of one or more chemical, peptide, or polypeptide moieties known in the art. The antibody may be conjugated with a chemical moiety.</p><p id="p0015" num="0015">A "derivative" may mean a peptide or polypeptide different other than in primary structure (amino acids and amino acid analogs). Derivatives may differ by being glycosylated, one form of post-translational modification. For example, peptides or polypeptides may exhibit glycosylation patterns due to expression in heterologous systems. If at least one biological activity is retained, then these peptides or polypeptides are derivatives according to the invention. Other derivatives may include fusion peptides or fusion polypeptides having a covalently modified N- or C-terminus, PEGylated peptides or polypeptides, peptides or<!-- EPO <DP n="6"> --> polypeptides associated with lipid moieties, alkylated peptides or polypeptides, peptides or polypeptides linked via an amino acid side-chain functional group to other peptides, polypeptides or chemicals, and additional modifications as would be understood in the art.</p><p id="p0016" num="0016">A "fragment" may mean a portion of a reference peptide or polypeptide.</p><p id="p0017" num="0017">A "homolog" may mean a peptide or polypeptide sharing a common evolutionary ancestor.</p><p id="p0018" num="0018">A "leader sequence" may be a nucleic acid encoding any peptide sequence that is linked and translated with a peptide or polypeptide of interest to allow the peptide or polypeptide of interest be properly routed through a eukaryotic cell's endoplasmic reticulum and Golgi complexes for the purposed of extracellular secretion from the cell's membrane. The leader peptide sequence may be derived from alkaline phosphatase. The leader sequence may have a DNA sequence comprising atgctgctgctgctgctgctgctgggcctgaggctacagctct ccctgggc.</p><p id="p0019" num="0019">A "liposome" may mean a tiny bubble (vesicle) made out of the same material as a cell membrane. A liposome be filled with drugs and used to deliver drugs for cancer and other diseases. A liposome may be filled with a vector. A liposome membrane may be made of phospholipids, which are molecules that have a head group and a tail group. The head of the liposome may be attracted to water, and the tail, which is made of a long hydrocarbon chain, is repelled by water. The tails may be repelled by water, and line up to form a surface away from the water. The lipids in the plasma membrane may be chiefly phospholipids like phosphatidylethanolamine and phosphatidylcholine. Liposomes may be composed of naturally-derived phospholipids with mixed lipid chains (like egg phosphatidylethanolamine), or of pure surfactant components like DOPE (dioleoylphosphatidylethanolamine).</p><p id="p0020" num="0020">A "peptide" or "polypeptide" may mean a linked sequence of amino acids and may be natural, synthetic, or a modification or combination of natural and synthetic.</p><p id="p0021" num="0021">"Substantially identical" may mean that a first and second amino acid sequence are at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%,or 99% over a region of 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100 amino acids .</p><p id="p0022" num="0022">"Treating," "treatment," or "to treat" each may mean to alleviate, suppress, repress, eliminate, prevent or slow the appearance of symptoms, clinical signs, or underlying pathology of a condition or disorder on a temporary or permanent basis. Preventing a condition or disorder<!-- EPO <DP n="7"> --> involves administering a agent of the present invention to a subject prior to onset of the disease. Suppressing a condition or disorder involves administering a agent of the present invention to a subject after induction of the condition or disorder but before its clinical appearance. Repressing the condition or disorder involves administering a agent of the present invention to a subject after clinical appearance of the disease.</p><p id="p0023" num="0023">A "variant" may mean means a peptide or polypeptide that differs in amino acid sequence by the insertion, deletion, or conservative substitution of amino acids, but retain at least one biological activity. Representative examples of "biological activity" include the ability to bind to a toll-like receptor and to be bound by a specific antibody. Variant may also mean a protein with an amino acid sequence that is substantially identical to a referenced protein with an amino acid sequence that retains at least one biological activity. A conservative substitution of an amino acid, i.e., replacing an amino acid with a different amino acid of similar properties (e.g., hydrophilicity, degree and distribution of charged regions) is recognized in the art as typically involving a minor change. These minor changes can be identified, in part, by considering the hydropathic index of amino acids, as understood in the art. <nplcit id="ncit0001" npl-type="s"><text>Kyte et al., J. Mol. Biol. 157:105-132</text></nplcit></p><p id="p0024" num="0024">(1982). The hydropathic index of an amino acid is based on a consideration of its hydrophobicity and charge. It is known in the art that amino acids of similar hydropathic indexes can be substituted and still retain protein function. In one aspect, amino acids having hydropathic indexes of ±2 are substituted. The hydrophilicity of amino acids can also be used to reveal substitutions that would result in proteins retaining biological function. A consideration of the hydrophilicity of amino acids in the context of a peptide permits calculation of the greatest local average hydrophilicity of that peptide, a useful measure that has been reported to correlate well with antigenicity and immunogenicity. <patcit id="pcit0001" dnum="US4554101A"><text>U.S. Patent No. 4,554,101</text></patcit>, incorporated fully herein by reference. Substitution of amino acids having similar hydrophilicity values can result in peptides retaining biological activity, for example immunogenicity, as is understood in the art. Substitutions may be performed with amino acids having hydrophilicity values within ±2 of each other. Both the hyrophobicity index and the hydrophilicity value of amino acids are influenced by the particular side chain of that amino acid. Consistent with that observation, amino acid substitutions that are compatible with biological function are understood to depend on the relative similarity of the amino acids, and particularly the side chains of those amino acids, as revealed by the hydrophobicity, hydrophilicity, charge, size, and other properties.<!-- EPO <DP n="8"> --></p><p id="p0025" num="0025">A "vector" may mean a nucleic acid sequence containing an origin of replication. A vector may be a plasmid, a yeast or a mammalian artificial chromosome. A vector may be a RNA or DNA vector. A vector may be either a self-replicating extrachromosomal vector or a vector which integrates into a host genome.</p><heading id="h0007"><b>2. Toll-Like Receptor</b></heading><p id="p0026" num="0026">Provided herein is a toll-like receptor (TLR), which may be a type of pattern recognition receptor (PRR). The TLR may recognize molecules that are conserved molecular products derived from pathogens that include Gram-positive, Gram-negative bacteria, fungi, and viruses, but are distinguishable from host molecules, collectively referred to as pathogen-associated molecular patterns (PAMPs). The TLR may also recognize endogenous molecules released from injured or dying cells, collectively referred to as damage-associated molecular pattern (DAMPs). A PAMP or DAMP may be a TLR agonist as further described below. The TLR may be a fragment, variant, analog, homolog or derivative that recruits adapter molecules within the cytoplasm of cells in order to propagate a signal. The TLR may be from a human or other mammalian species such as rhesus monkey, mouse, or rat. The TLR may be at least 30-99% identical to a TLR that recruits adapter molecules within the cytoplasm of cells in order to propagate a signal.</p><p id="p0027" num="0027">The TLR may be one of the between ten and fifteen types of TLR that are estimated to exist in most mammalian species. The TLR may be one of the 13 TLR (named simply TLR1 to TLR13) that have been identified in humans and mice together, or may be an equivalent form that has been found in other mammalian species. The TLR may be one of the 11 members (TLR1-TLR11) that have been identified in humans.</p><p id="p0028" num="0028">The TLR may be expressed by different types of immune cells, and may be located on the cell surface or in the cell cytoplasm. The TLR may be expressed on cancer cells. The TLR may be expressed by normal epithelial cells in the digestive system, normal keratinocytes in the skin, alveolar and bronchial epithelial cells, and epithelial cells of the female reproductive tract. These cells lining an organ may be the first line of defense against invasion of micoorganisms, and TLRs expressed in epithelial cells may have a crucial role in the regulation of proliferation and apoptosis.</p><p id="p0029" num="0029">The TLR-expressing cancer cell may be selected from the following table:<!-- EPO <DP n="9"> -->
<tables id="tabl0001" num="0001"><table frame="all"><title>Table 1 TLR expression in Human Cancer cells</title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="41mm"/><colspec colnum="2" colname="col2" colwidth="50mm"/><thead><row><entry align="center" valign="top"><b><u>TYPE OF CANCER</u></b></entry><entry align="center" valign="top"><b><u>TLR</u></b></entry></row></thead><tbody><row><entry>Gastric cancer</entry><entry>TLR2, TLR4, TLR5, TLR9</entry></row><row><entry>Colorectal cancer</entry><entry>TLR2, TLR3, TLR4, TLR5, TLR9</entry></row><row><entry>Ovarian cancer</entry><entry>TLR2, TLR3, TLR4, TLR5</entry></row><row><entry>Cervical cancer</entry><entry>TLR3, TLR4, TLR5, TLR9</entry></row><row><entry>Lung cancer</entry><entry>TLR2, TLR3, TLR4, TLR9</entry></row><row><entry>Prostate cancer</entry><entry>TLR4, TLR9</entry></row><row><entry>Melanoma</entry><entry>TLR2, TLR3, TLR4</entry></row><row><entry>Brain cancer</entry><entry>TLR2, TLR4</entry></row><row><entry>Breast cancer</entry><entry>TLR2, TLR3, TLR4, TLR9</entry></row><row><entry>Hepatocellular carcinoma</entry><entry>TLR2, TLR3, TLR4, TLR6, TLR9</entry></row><row><entry>Laryngeal cancer</entry><entry>TLR2, TLR3, TLR4</entry></row></tbody></tgroup></table></tables></p><p id="p0030" num="0030">The TLR expressed on cancer cells may upregulate the NF-κB cascade and produce anti-apoptotic proteins that contribute to carcinogenesis and cancer cell proliferation.</p><p id="p0031" num="0031">Four adapter molecules of TLRs are known to be involved in signaling. These proteins are known as myeloid differentiation factor 88 (MyD88), Tirap (also called Mal), Trif, and Tram. The adapters activate other molecules within the cell, including certain protein kinases (IRAK1, IRAK4, TBK1, and IKKi) that amplify the signal, and ultimately lead to the induction or suppression of genes that orchestrate the inflammatory response. TLR signaling pathways during pathogen recognition may induce immune reactions via extracellular and intracellular pathways mediated by MyD88, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and mitogen-associated protein kinase (MAPK). In all, thousands of genes are activated by TLR signaling, and collectively, the TLR constitute one of the most pleiotropic, yet tightly regulated gateways for gene modulation.</p><p id="p0032" num="0032">TLRs together with the Interleukin-1 receptors form a receptor superfamily, known as the "Interleukin-1 Receptor/Toll-Like Receptor Superfamily." All members of this family have in common a so-called TIR (Toll-IL-1 receptor) domain. Three subgroups of TIR domains may exist. Proteins with subgroup I TIR domains are receptors for interleukins that are produced by macrophages, monocytes and dendritic cells and all have extracellular Immunoglobulin (Ig) domains. Proteins with subgroup II TIR domains are classical TLRs, and bind directly or indirectly to molecules of microbial origin. A third subgroup of proteins containing TIR domains (III) consists of adaptor proteins that are exclusively cytosolic and mediate signaling from<!-- EPO <DP n="10"> --> proteins of subgroups 1 and 2. The TLR may be a fragment, variant, analog, homolog or derivative that retains either a subgroup I TIR domain, subgroup II TIR domain, or subgroup III TIR domain.</p><p id="p0033" num="0033">The TLR may function as a dimer. For example, although most TLRs appear to function as homodimers, TLR2 forms heterodimers with TLR1 or TLR6, each dimer having a different ligand specificity. The TLR may also depend on other co-receptors for full ligand sensitivity, such as in the case of TLR4's recognition of LPS, which requires MD-2. CD14 and LPS Binding Protein (LBP) are known to facilitate the presentation of LPS to MD-2.</p><heading id="h0008"><b>a. TLR1</b></heading><p id="p0034" num="0034">The TLR may be TLR1, which recognizes PAMPs with a specificity for gram-positive bacteria. TLR1 has also been designated as CD281.</p><heading id="h0009"><b>b. TLR5</b></heading><p id="p0035" num="0035">The TLR may be Toll-like receptor 5. The protein encoded by the TLR-5 may play a fundamental role in pathogen recognition and activation of innate immunity. TLR-5 may recognize PAMPs that are expressed on infectious agents, and mediate the production of cytokines necessary for the development of effective immunity. TLR-5 may recognize bacterial flagellin, a principal component of bacterial flagella and a virulence factor. The activation of the TLR may mobilize the nuclear factor NF-κB and stimulate tumor necrosis factor-alpha production.</p><heading id="h0010"><b>3. Toll-like Receptor Agonist</b></heading><p id="p0036" num="0036">Also provided herein is a TLR agonist. The TLR agonist may be a PAMP, which may be conserved molecular product derived from a pathogen. The pathogen may be a Gram-positive bacterium, Gram-negative bacterium" fungus, or virus. The TLR agonist may be a damage-associated molecular pattern (DAMP) ligand, which may be an endogenous molecule released from injured or dying cells. A DAMP or PAMP may initiate an immune response through TLR signals and recruit adapter molecules within the cytoplasm of cells in order to propagate a signal. The TLR agonist may be an agonist for the TLR, which may be a ligand from the following in Table 2:<!-- EPO <DP n="11"> -->
<tables id="tabl0002" num="0002"><table frame="all"><title>Table 2 TLRs and Ligands</title><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="21mm"/><colspec colnum="2" colname="col2" colwidth="70mm"/><colspec colnum="3" colname="col3" colwidth="75mm"/><thead><row><entry valign="top"><b>TLR</b></entry><entry valign="top"><b>Ligand DAMP</b></entry><entry valign="top"><b>Ligand PAMP</b></entry></row></thead><tbody><row><entry>TLR1</entry><entry/><entry>Triacyl lipoproteins</entry></row><row><entry>TLR2</entry><entry>Heat Shock proteins</entry><entry>Peptidoglycan</entry></row><row><entry/><entry>HMGB1 (high mobility group box 1-amphoterin)</entry><entry>Lipoprotein</entry></row><row><entry/><entry/><entry>Lipoteichoic acid</entry></row><row><entry/><entry/><entry>Zymosan</entry></row><row><entry>TLR3</entry><entry>Self dsRNA</entry><entry>Viral dsRNA</entry></row><row><entry>TLR4</entry><entry>Heat shock proteins</entry><entry>Heat shock proteins</entry></row><row><entry/><entry>Fibrinogen</entry><entry>Lipopolysaccharides</entry></row><row><entry/><entry>Heparan sulfate</entry><entry>RSV fusion protein</entry></row><row><entry/><entry>Fibronectin</entry><entry>MMTV (Mouse mammary tumor virus) envelope proteins</entry></row><row><entry/><entry>Hyaluronic acid</entry><entry>Paclitaxel</entry></row><row><entry/><entry>HMGB1</entry><entry/></row><row><entry>TLR5</entry><entry/><entry>flagellin</entry></row><row><entry>TLR6</entry><entry/><entry>Lipoteichoic acid</entry></row><row><entry/><entry/><entry>Triacyl lipoproteins</entry></row><row><entry/><entry/><entry>zymosan</entry></row><row><entry>TLR7/TLR8</entry><entry>Self ssRNA</entry><entry>Viral ssRNA</entry></row><row><entry>TLR9</entry><entry>Self DNA</entry><entry>Bacterial and viral DNA</entry></row><row><entry>TLR10</entry><entry/><entry/></row><row><entry>TLR11</entry><entry/><entry>Profilin</entry></row></tbody></tgroup></table></tables></p><p id="p0037" num="0037">The TLR agonist may be a fragment, variant, analog, homology or derivative of a PAMP or DAMP that binds a TLR and induces TLR-mediated activity, such as activation of NF-κB activity. The TLR agonsist fragment, variant, analog, homolog, or derivative may be at least 30-99% identical to amino acids of a TLR-agonist and induce TLR-mediated activity.</p><p id="p0038" num="0038">The TLR agonist may target a TLR such as TLR-5. The TLR agonist may be an agonist of TLR-5 and stimulate TLR-5 activity. The TLR agonist may be an anti-TLR5 antibody or other small molecule. The TLR agonist may be flagellin.</p><p id="p0039" num="0039">The flagellin may also be a flagellin or flagellin-related polypeptide. The flagellin may be from any source, including a variety of Gram-positive and Gram-negative bacterial species. The flagellin may be a flagellin polypeptide from any Gram-positive or Gram-negative bacterial species including, but not limited to, a flagellin polypeptide disclosed in <patcit id="pcit0002" dnum="US2003000044429A"><text>U.S. Pat. Pub. No. 2003/000044429</text></patcit>. For example,<!-- EPO <DP n="12"> --> the flagellin may have an amino acid sequence from a bacterial species depicted in <figref idrefs="f0009 f0010 f0011 f0012 f0013 f0014 f0015 f0016 f0017 f0018">Figure 7</figref> of <patcit id="pcit0003" dnum="US20030044429A"><text>U.S. Patent Publication No. 2003/0044429</text></patcit>. The nucleotide sequences encoding the flagellin polypeptides listed in <figref idrefs="f0009 f0010 f0011 f0012 f0013 f0014 f0015 f0016 f0017 f0018">Figure 7</figref> of <patcit id="pcit0004" dnum="US20030044429A"><text>U.S. 2003/0044429</text></patcit> are publicly available at sources including the NCBI Genbank database. The flagellin may also be a flagellin peptide corresponding to an Accession number listed in the BLAST results shown in Fig. 25 of <patcit id="pcit0005" dnum="US2003000044429A"><text>U.S. Patent Pub. 2003/000044429</text></patcit>, or a variant thereof. The flagellin may also be a flagellin polypeptide as disclosed in <patcit id="pcit0006" dnum="US20090011982A"><text>U.S. Patent Appl. Publication No. 2009/0011982</text></patcit>. The flagellin maybe anyone of a flagellin polypeptide as disclosed in <figref idrefs="f0008">Figures 6</figref> and <figref idrefs="f0009 f0010 f0011 f0012 f0013 f0014 f0015 f0016 f0017 f0018">7</figref> herein.</p><p id="p0040" num="0040">The flagellin may be a fragment, variant, analog, homology or derivative of a flagellin that binds TLR5 and induces TLR5-mediated activity, such as activation of NF-κB activity. A fragment, variant, analog, homolog, or derivative of flagellin may be at least 30-99% identical to amino acids of a flagellin that binds TLR5 and induces TLR5-mediated activity.</p><p id="p0041" num="0041">The flagellin may be from a species of Salmonella, a representative example of which is S.dublin (encoded by GenBank Accession Number M84972). The flagellin related-polypeptide may be a fragment, variant, analog, homolog, or derivative of M84972, or combination thereof, that binds to TLR5 and induces TLR5-mediated activity, such as activation of NF-kB activity. A fragment, variant, analog, homolog, or derivative of flagellin may be obtained by rational-based design based on the domain structure of Flagellin and the conserved structure recognized by TLR5.</p><p id="p0042" num="0042">The flagellin may comprise at least 10, 11, 12, or 13 of the 13 conserved amino acids shown in <figref idrefs="f0007">Fig. 5</figref> (positions 89, 90, 91, 95, 98, 101, 115, 422, 423, 426, 431, 436 and 452). The flagellin may be at least 30-99% identical to amino acids 1 174 and 418 505 of M84972. Fig. 26 of <patcit id="pcit0007" dnum="US20090011982A"><text>U.S. Patent Appl Publication No. 2009/0011982</text></patcit> lists the percentage identity of the amino- and carboxy-terminus of flagellin with known TLR-5 stimulating activity, as compared to M84972.</p><p id="p0043" num="0043">The flagellin may be the major component of bacterial flagellum. The flagellin may be composed of three domains (<figref idrefs="f0006">Fig. 4</figref>). Domain 1 (D1) and domain 2 (D2) may be discontinuous and may be formed when residues in the amino terminus and carboxy terminus are juxtaposed by the formation of a hairpin structure. The amino and carboxy terminus comprising the D1 and D2 domains may be most conserved, whereas the middle hypervariable domain (D3) may be highly<!-- EPO <DP n="13"> --> variable. Studies with a recombinant protein containing the amino D1 and D2 and carboxyl D1 and D2 separated by an Escherichia coli hinge (ND1-2/ECH/CD2) indicate that D1 and D2 may be bioactive when coupled to an ECH element. This chimera, but not the hinge alone, may induce IkBa degradation, NF-kB activation, and NO and IL-8 production in two intestinal epithelial cell lines. The non-conserved D3 domain may be on the surface of the flagellar filament and may contain the major antigenic epitopes. The potent proinflammatory activity of flagellin may reside in the highly conserved N and C D1 and D2 regions (See <figref idrefs="f0006">Figure 4</figref>).</p><p id="p0044" num="0044">The flagellin may induce NF-kB activity by binding to Toll-like receptor 5 (TLR5). The TLR may recognize a conserved structure that is particular to the flagellin. The conserved structure may be composed of a large group of residues that are somewhat permissive to variation in amino acid content. <nplcit id="ncit0002" npl-type="s"><text>Smith et al., Nat Immunol. 4:1247-53 (2003</text></nplcit>), the contents of which are incorporated herein by reference, have identified 13 conserved amino acids in flagellin that are part of the conserved structure recognized by TLR5. The 13 conserved amino acids of flagellin that may be important for TLR5 activity are shown in <figref idrefs="f0007">Fig. 5</figref>.</p><p id="p0045" num="0045">Numerous deletional mutants of flagellin have been made that retain at least some TLR5 stimulating activity. The flagellin may be such a deletional mutant, and may be a deletional mutant disclosed in the Examples herein. The flagellin may comprise a sequence translated from GenBank Accession number D13689 missing amino acids 185-306 or 444-492, or from GenBank Accession number M84973 missing amino acids 179-415, or a variant thereof.</p><p id="p0046" num="0046">The flagellin may comprise transposon insertions and changes to the variable D3 domain. The D3 domain may be substituted in part, or in whole, with a hinge or linker polypeptide that allows the D1 and D2 domains to properly fold such that the variant stimulates TLR5 activity. The variant hinge elements may be found in the <i>E.coli</i> MukB protein and may have a sequence as set forth in SEQ ID NOS: 3 and 4, or a variant thereof.</p><p id="p0047" num="0047">The flagellin as described above may further comprise a leader sequence. The flagellin further comprising a leader sequence may be CBLB502S.</p><heading id="h0011"><b>4. Agent</b></heading><p id="p0048" num="0048">This invention also relates to an agent comprising a therapeutically effective amount of a TLR and TLR agonist. The agent may deliver the TLR separately from the TLR agonist. The agent may be a vector. The vector may comprise a first nucleic acid encoding the TLR and a second nucleic acid comprising the TLR agonist. The vector may be capable of transducing<!-- EPO <DP n="14"> --> mammalian cells. The vector may be capable of bi-cistronic expression of the TLR and/or TLR agonist using strong promoters. The vector may comprise only a gene encoding the TLR, which may be controlled by a strong promoter. The vector may be delivered into a mammalian cell by a virus or liposome related vector system. The virus vector system may be an adenovirus or a cytomegalovirus.</p><p id="p0049" num="0049">The agent may be a liposome harboring the vector. The liposome maybe capable of transducing mammalian cells and delivering the vector for expression.</p><p id="p0050" num="0050">The agent may be a drug formulation that simultaneously induces expression and activates the TLR, thereby exposing tumor or infected cells to the host immune system imitating the situation of a massive penetration through the intestinal wall. The agent may be a drug formulation that expresses the TLR in combination with the TLR agonist, and may be delivered systematically in solution for administration such as intramuscularly. The agent may be a drug formulation that expresses the TLR in combination with the TLR agonist, which may be expressed from the same vector, such as an adenoviral or cytomegalovirus vector system. The agent may be a drug formulation that expresses the TLR in combination with the TLR agonist expressed in the form of a nano-particle, which may carry a functional agonist to the cell surface of a mammalian cell.</p><p id="p0051" num="0051">The agent may be a pharmaceutical agent comprising the drug formulation described above, which may be produced using methods well known in the art. The agent may also comprise a coagent.</p><p id="p0052" num="0052">The vector may comprise a first nucleic acid encoding TLR5 and a second nucleic acid comprising flagellin. The vector may be capable of expressing TLR5 and/or flagellin using a strong promoter. The expression vector may further comprise a leader sequence cloned upstream of the gene encoding the TLR or TLR5 and/or flagellin. The expression vector may be pCD515 based vector system. The expression vector may be pCD515-CMV-hTLRS-EF1-502 as described in <figref idrefs="f0001">Figure 1A</figref>. The expression vector may be pCD515-CMV-hTLR5 as described in <figref idrefs="f0002">Figure 1B</figref>. The expression vector may be pCD515-CMV-Sseap-502 as described in <figref idrefs="f0003">Figure 1C</figref>.</p><p id="p0053" num="0053">The agent may be drug formulation that simultaneously induces expression and activates a TLR thereby exposing tumor or infected cells to the host immune system imitating the situation of a massive penetration through the intestinal wall. The drug formulation may be in the form of<!-- EPO <DP n="15"> --> a viral expression system harboring the vector. The drug formulation may be an adenovirus expression functional human TLR5 in combination with:</p><p id="p0054" num="0054">the TLR agonist, delivered systematically in solution for administration, such as intramuscularly;</p><p id="p0055" num="0055">the TLR agonist, expressed from the same adenoviral vector as the TLR; or</p><p id="p0056" num="0056">the TLR agonist, expressed in the form of nano-particles carrying functional TLR agonist, such as flagellin, which may be derived from CBLB502, on their surface. The nano-particle may be on the basis of a bacteriophage T7, or fully formed to retain its biological activity. The nano-formulation may provide for dose-dependent, NF-κB-responsive reporter activation, and may result in cell internalization by endocytosis for effective immunization approach (Mobian AP-A).</p><heading id="h0012"><b>a. Administration</b></heading><p id="p0057" num="0057">Administration of the agents using the method described herein may be orally, parenterally, sublingually, transdermally, rectally, transmucosally, topically, via inhalation, via buccal administration, or combinations thereof. Parenteral administration includes, but is not limited to, intravenous, intraarterial, intraperitoneal, subcutaneous, intramuscular, intrathecal, and intraarticular. For veterinary use, the agent may be administered as a suitably acceptable formulation in accordance with normal veterinary practice. The veterinarian can readily determine the dosing regimen and route of administration that is most appropriate for a particular animal. The agents may be administered to a human patient, cat, dog, large animal, or an avian.</p><p id="p0058" num="0058">The agent may be administered simultaneously or metronomically with other treatments. The term "simultaneous" or "simultaneously" as used herein, means that the agent and other treatment be administered within 48 hours, preferably 24 hours, more preferably 12 hours, yet more preferably 6 hours, and most preferably 3 hours or less, of each other. The term "metronomically" as used herein means the administration of the agent at times different from the other treatment and at a certain frequency relative to repeat administration.</p><p id="p0059" num="0059">The agent may be administered at any point prior to another treatment including about 120 hr, 118 hr, 116 hr, 114 hr, 112 hr, 110 hr, 108 hr, 106 hr, 104 hr, 102 hr, 100 hr, 98 hr, 96 hr, 94 hr, 92 hr, 90 hr, 88 hr, 86 hr, 84 hr, 82 hr, 80 hr, 78 hr, 76 hr, 74 hr, 72 hr, 70 hr, 68 hr, 66 hr, 64 hr, 62 hr, 60 hr, 58 hr, 56 hr, 54 hr, 52 hr, 50hr, 48 hr, 46 hr, 44 hr, 42 hr, 40 hr, 38 hr, 36 hr, 34 hr, 32 hr, 30 hr, 28 hr, 26 hr, 24 hr, 22 hr, 20 hr, 18 hr, 16 hr, 14 hr, 12 hr, 10 hr, 8 hr, 6 hr, 4<!-- EPO <DP n="16"> --> hr, 3 hr, 2 hr, 1 hr, 55 mins., 50 mins., 45 mins., 40 mins., 35 mins., 30 mins., 25 mins., 20 mins., 15 mins, 10 mins, 9 mins, 8 mins, 7 mins., 6 mins., 5 mins., 4 mins., 3 mins, 2 mins, and 1 mins. The agent may be administered at any point prior to a second treatment of the agent including about 120 hr, 118 hr, 116 hr, 114 hr, 112 hr, 110 hr, 108 hr, 106 hr, 104 hr, 102 hr, 100 hr, 98 hr, 96 hr, 94 hr, 92 hr, 90 hr, 88 hr, 86 hr, 84 hr, 82 hr, 80 hr, 78 hr, 76 hr, 74 hr, 72 hr, 70 hr, 68 hr, 66 hr, 64 hr, 62 hr, 60 hr, 58 hr, 56 hr, 54 hr, 52 hr, 50hr, 48 hr, 46 hr, 44 hr, 42 hr, 40 hr, 38 hr, 36 hr, 34 hr, 32 hr, 30 hr, 28 hr, 26 hr, 24 hr, 22 hr, 20 hr, 18 hr, 16 hr, 14 hr, 12 hr, 10 hr, 8 hr, 6 hr, 4 hr, 3 hr, 2 hr, 1 hr, 55 mins., 50 mins., 45 mins., 40 mins., 35 mins., 30 mins., 25 mins., 20 mins., 15 mins., 10 mins., 9 mins., 8 mins., 7 mins., 6 mins., 5 mins., 4 mins., 3 mins, 2 mins, and 1 mins.</p><p id="p0060" num="0060">The agent may be administered at any point after another treatment including about 1min, 2 mins., 3 mins., 4 mins., 5 mins., 6 mins., 7 mins., 8 mins., 9 mins., 10 mins., 15 mins., 20 mins., 25 mins., 30 mins., 35 mins., 40 mins., 45 mins., 50 mins., 55 mins., 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 10 hr, 12 hr, 14 hr, 16 hr, 18 hr, 20 hr, 22 hr, 24 hr, 26 hr, 28 hr, 30 hr, 32 hr, 34 hr, 36 hr, 38 hr, 40 hr, 42 hr, 44 hr, 46 hr, 48 hr, 50 hr, 52 hr, 54 hr, 56 hr, 58 hr, 60 hr, 62 hr, 64 hr, 66 hr, 68 hr, 70 hr, 72 hr, 74 hr, 76 hr, 78 hr, 80 hr, 82 hr, 84 hr, 86 hr, 88 hr, 90 hr, 92 hr, 94 hr, 96 hr, 98 hr, 100 hr, 102 hr, 104 hr, 106 hr, 108 hr, 110 hr, 112 hr, 114 hr, 116 hr, 118 hr, and 120 hr. The agent may be administered at any point prior after a second treatment of the agent including about 120 hr, 118 hr, 116 hr, 114 hr, 112 hr, 110 hr, 108 hr, 106 hr, 104 hr, 102 hr, 100 hr, 98 hr, 96 hr, 94 hr, 92 hr, 90 hr, 88 hr, 86 hr, 84 hr, 82 hr, 80 hr, 78 hr, 76 hr, 74 hr, 72 hr, 70 hr, 68 hr, 66 hr, 64 hr, 62 hr, 60 hr, 58 hr, 56 hr, 54 hr, 52 hr, 50hr, 48 hr, 46 hr, 44 hr, 42 hr, 40 hr, 38 hr, 36 hr, 34 hr, 32 hr, 30 hr, 28 hr, 26 hr, 24 hr, 22 hr, 20 hr, 18 hr, 16 hr, 14 hr, 12 hr, 10 hr, 8 hr, 6 hr, 4 hr, 3 hr, 2 hr, 1 hr, 55 mins., 50 mins., 45 mins., 40 mins., 35 mins., 30 mins., 25 mins., 20 mins., 15 mins., 10 mins., 9 mins., 8 mins., 7 mins., 6 mins., 5 mins., 4 mins., 3 mins, 2 mins, and 1 mins.</p><heading id="h0013"><b>b. Formulation</b></heading><p id="p0061" num="0061">The method may comprise administering the agent. Agents provided herein may be in the form of tablets or lozenges formulated in a conventional manner. For example, tablets and capsules for oral administration may contain conventional excipients may be binding agents, fillers, lubricants, disintegrants and wetting agents. Binding agents include, but are not limited to, syrup, accacia, gelatin, sorbitol, tragacanth, mucilage of starch and polyvinylpyrrolidone. Fillers<!-- EPO <DP n="17"> --> may be lactose, sugar, microcrystalline cellulose, maizestarch, calcium phosphate, and sorbitol. Lubricants include, but are not limited to, magnesium stearate, stearic acid, talc, polyethylene glycol, and silica. Disintegrants may be potato starch and sodium starch glycollate. Wetting agents may be sodium lauryl sulfate. Tablets may be coated according to methods well known in the art.</p><p id="p0062" num="0062">Agents provided herein may also be liquid formulations such as aqueous or oily suspensions, solutions, emulsions, syrups, and elixirs. The agents may also be formulated as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may contain additives such as suspending agents, emulsifying agents, nonaqueous vehicles and preservatives. Suspending agent may be sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminum stearate gel, and hydrogenated edible fats. Emulsifying agents may be lecithin, sorbitan monooleate, and acacia. Nonaqueous vehicles may be edible oils, almond oil, fractionated coconut oil, oily esters, propylene glycol, and ethyl alcohol. Preservatives may be methyl or propyl p-hydroxybenzoate and sorbic acid.</p><p id="p0063" num="0063">Agents provided herein may also be formulated as suppositories, which may contain suppository bases such as cocoa butter or glycerides. Agents provided herein may also be formulated for inhalation, which may be in a form such as a solution, suspension, or emulsion that may be administered as a dry powder or in the form of an aerosol using a propellant, such as dichlorodifluoromethane or trichlorofluoromethane. Agents provided herein may also be formulated as transdermal formulations comprising aqueous or nonaqueous vehicles such as creams, ointments, lotions, pastes, medicated plaster, patch, or membrane.</p><p id="p0064" num="0064">Agents provided herein may also be formulated for parenteral administration such as by injection, intratumor injection or continuous infusion. Formulations for injection may be in the form of suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulation agents including, but not limited to, suspending, stabilizing, and dispersing agents. The agent may also be provided in a powder form for reconstitution with a suitable vehicle including, but not limited to, sterile, pyrogen-free water.</p><p id="p0065" num="0065">Agents provided herein may also be formulated as a depot preparation, which may be administered by implantation or by intramuscular injection. The agents may be formulated with<!-- EPO <DP n="18"> --> suitable polymeric or hydrophobic materials (as an emulsion in an acceptable oil, for example), ion exchange resins, or as sparingly soluble derivatives (as a sparingly soluble salt, for example).</p><heading id="h0014"><b>c. Dosage</b></heading><p id="p0066" num="0066">The method may comprise administering a therapeutically effective amount of the agent to a patient in need thereof. The therapeutically effective amount required for use in therapy varies with the nature of the condition being treated, the length of time desired to activate TLR activity, and the age/condition of the patient. In general, however, doses employed for adult human treatment typically are in the range of 0.001 mg/kg to about 200 mg/kg per day. The dose may be about 1 mg/kg to about 100 mg/kg per day. The desired dose may be conveniently administered in a single dose, or as multiple doses administered at appropriate intervals, for example as two, three, four or more sub-doses per day. Multiple doses may be desired, or required.</p><p id="p0067" num="0067">The dosage may be at any dosage such as about 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.4 mg/kg, 0.5 mg/kg, 0.6 mg/kg, 0.7 mg/kg, 0.8 mg/kg, 0.9 mg/kg, 1 mg/kg, 25 mg/kg, 50 mg/kg, 75 mg/kg, 100 mg/kg, 125 mg/kg, 150 mg/kg, 175 mg/kg, 200 mg/kg, 225 mg/kg, 250 mg/kg, 275 mg/kg, 300 mg/kg, 325 mg/kg, 350 mg/kg, 375 mg/kg, 400 mg/kg, 425 mg/kg, 450 mg/kg, 475 mg/kg, 500 mg/kg, 525 mg/kg, 550 mg/kg, 575 mg/kg, 600 mg/kg, 625 mg/kg, 650 mg/kg, 675 mg/kg, 700 mg/kg, 725 mg/kg, 750 mg/kg, 775 mg/kg, 800 mg/kg, 825 mg/kg, 850 mg/kg, 875 mg/kg, 900 mg/kg, 925 mg/kg, 950 mg/kg, 975 mg/kg or 1 mg/kg.</p><heading id="h0015"><b>5. Method for Treating Cancer</b></heading><p id="p0068" num="0068">Provided herein is a vector and agent for use in treating cancer by administering to a mammal in need thereof the agent. They can also be used for immunotherapy against cancer by conversion of tumor cells into a TLR agonist-responsive state with targeted intratumor stimulation of TLR, thereby focusing an immune response on the tumor. Primary tumors can be treated prior to surgical removal in order to reduce the risk of metastasis development, as well as to treat of other tumor nodules. The method may comprise intratumor injection. The agent may be injected into a primary tumor prior to surgical removal to reduce the risk of metastasis development, as well as to treat other tumor nodules. Any tumor that is accessible for adenovirus intratumor injection may be treated.</p><p id="p0069" num="0069">A variety of cancers may be treated according to this invention, including carcinoma, bladder (including accelerated and metastatic bladder cancer), breast, colon (including colorectal<!-- EPO <DP n="19"> --> cancer), kidney, liver, lung (including small and non-small cell lung cancer and lung adenocarcinoma), ovary, prostate, testes, genitourinary tract, lymphatic system, rectum, larynx, pancreas (including exocrine pancreatic carcinoma), esophagus, stomach, gall bladder, cervix, thyroid, and skin (including squamous cell carcinoma); hematopoietic tumors of lymphoid lineage including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma, histiocytic lymphoma, and Burketts lymphoma; hematopoietic tumors of myeloid lineage including acute and chronic myelogenous leukemias, myelodysplastic syndrome, myeloid leukemia, and promyelocytic leukemia; tumors of the central and peripheral nervous system including astrocytoma, neuroblastoma, glioma, and schwannomas; tumors of mesenchymal origin including fibrosarcoma, rhabdomyoscarcoma, and osteosarcoma; and other tumors including melanoma, xenoderma pigmentosum, keratoactanthoma, seminoma, thyroid follicular cancer, teratocarcinoma, and cancers of the gastrointestinal tract or the abdominopelvic cavity.</p><p id="p0070" num="0070">The method may be combined with other methods for treating cancer, including use of an immunostimulant, cytokine, or chemotherapeutic. The immunostimulant may be a growth hormone, prolactin or vitamin D.</p><heading id="h0016"><b>6. Treatment of Infected Cells</b></heading><p id="p0071" num="0071">Provided herein is a vector and agent for use in treating an infectious disease by the simultaneous delivery of transduced cells by the agent. They may be used to treat viral, bacterial protozoan parasite or fungal infection. Any infectious disease can be treated by it by using intracellular injection resulting in autocrine activation of TLR signaling of infected cells with minimal systemic effect and thereby enabling to attract innate immune response specific to the infected cells. Treatment may be combined with other therapies for treating viral, bacterial, protozoan parasite or fungi infections.</p><p id="p0072" num="0072">Treatment may comprise administering the agent. Treatment may comprise administration of a vaccine comprising the agent, and may be used in combination with any other vaccination, which may comprise a construct expressing an antigen of choice.<!-- EPO <DP n="20"> --></p><heading id="h0017"><b>Example 1</b></heading><heading id="h0018"><b>Synthesis of Bi-cistronic expression TLR5/flagellin vector and Treatment of Tumor Cells</b></heading><p id="p0073" num="0073">Vector constructs were created for expressing Toll-like receptor 5 (TLR-5) and flagellin CBLB502. Vector pCD515 was used as a backbone for these constructs. The cDNA sequence of human TLR-5 and the DNA encoding the toll-like receptor agonist's CBLB502 were individually fused with leader peptide derived from alkaline phosphatase enabling routing of the expressed protein through the endoplasmic reticulum (ER) and Golgi towards extracellular secretion.</p><p id="p0074" num="0074">The pCD515-CMV-hTLR5-EF1-502s vector construct expressed the secreted form of CBLB502 flagellin (CBLB502S) and the toll-like receptor 5 (TLR5) at the cell surfcace. This adenoviral vector required modification of the CBLB502 to reach its effective synthesis and secretion by mammalian cells. The adenovirus construct comprises the leader nucleic acid sequence (Atgctgctgctgctgctgctgctgggcctgaggctacagctctccctgggc) derived from alkaline phosphatase and was cloned upstream of the truncated Salmonella flagellin (fliC) gene (see <nplcit id="ncit0003" npl-type="s"><text>Burdelya et al., Science 320:226-230 (2008</text></nplcit>) to encode a secretable form of flagellin (i.e., CBLB502S). An EF1 (elongation factor la) promoter was cloned upstream of this cassette encoding CBLB502S. The TLR5 gene was derived from human and has the amino acid sequence as shown in <figref idrefs="f0023">Figure 9</figref>. A CMV promoter was cloned upstream of the TLR5 gene. This construct co-expresses TLR5 and CBLB502S. This construct is shown in <figref idrefs="f0001">Figure 1A</figref>.</p><p id="p0075" num="0075">The pCD515-CMV-hTLR5 expression vector was constructed to express the form of human TLR-5 (see <figref idrefs="f0023">Figure 9</figref>). The adenovirus construct comprises a strong CMV promoter cloned upstream of the hTLR5 cassette. This construct is shown in <figref idrefs="f0002">Figure 1B</figref>.</p><p id="p0076" num="0076">The pCD515-CMV-Sseap-502 expression vector was constructed to express the secreted flagellin CBLB502 and the toll-like. The adenovirus construct comprises a strong CMV promoter cloned upstream of the leader sequence SEAP 502 flagellin (fliC) gene. This construct is shown in <figref idrefs="f0003">Figure 1C</figref>. [Need cloning information]<!-- EPO <DP n="21"> --></p><heading id="h0019"><b>Example 2</b></heading><heading id="h0020"><b>Synthesis of Bi-cistronic expression TLR5/flagellin vector and Treatment of Tumor Cells</b></heading><p id="p0077" num="0077">Two reporter mammalian cell lines, both expressing NF-kB-responsive GFP and differing in their TLR5 status, were transduced with vector constructs pCD515, pCD515-CMV-hTLR5-EF1-502s, pCD515-CMV-hTLR5-502, pCD515-CMV-hTLR5, and pCD515-CMV-Sseap-502 (see Table 3 below).
<tables id="tabl0003" num="0003"><table frame="all"><title>Table 3 Activity of adenoviral constructs as TLR5 signaling activators</title><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="93mm"/><colspec colnum="2" colname="col2" colwidth="35mm"/><colspec colnum="3" colname="col3" colwidth="39mm"/><thead><row><entry valign="top"><b>Treatment</b></entry><entry valign="top"><b>Report Line-293-null</b></entry><entry valign="top"><b>Reporter Line-293-TLR</b></entry></row></thead><tbody><row><entry>CBLB502</entry><entry>-</entry><entry>+</entry></row><row><entry>Ad5 (control) (pCD515)</entry><entry>-</entry><entry>-</entry></row><row><entry>Ad5 (TLR5) (pCD515-CMV-hTLRS)</entry><entry>-</entry><entry>-</entry></row><row><entry>Ad5(TLR5) + CBLB502 (pCD515-CMV-hTLR5-EF1-502)</entry><entry>+</entry><entry>+</entry></row><row><entry>Ad5 (CBLB502S) (pCD515-CMV-Sseap-502)</entry><entry>-</entry><entry>+</entry></row><row><entry>Ad5 (TLR5) (pCD515-CMV-hTLR5) + Ad5(CBLB502S) (pCD515-CMV-hTLR5-EF1-502s)</entry><entry>+</entry><entry>+</entry></row><row><entry>Ad5 (CBLB502S + TLR5) (pCD515-CMV-hTLR5-EF1-502s)</entry><entry>+</entry><entry>+</entry></row></tbody></tgroup></table></tables></p><p id="p0078" num="0078">Vector co-expressing TLR5 and TLR5 agonist CBLB502S was sufficient to induce expression of NF-kB reporter in 293-null cells that do not express any of known TLRs and which cannot be activated by TLR5 agonist alone. This experiment demonstrates that TLR5 and flagellin CBLB502S can work in trans or in cis to activate TLR5 signaling.</p><heading id="h0021"><b>Example 3</b></heading><p id="p0079" num="0079">To test antitumor effects of bi-cistronic adenovirus having (pCD515-CMV-hTLR5-EF1-502s), 10 ml of the adenoviral suspension (1012-1011 IU/ml) were injected into one of two s.c. growing syngeneic tumors in Balb/c mice originating from CT26 mouse colon carcinoma cells when tumors reached 3-5mm in diameter and tumor size was monitored until control non-injected tumors reached size limit requiring termination of the experiment. Control mice were<!-- EPO <DP n="22"> --> injected (again, one tumor out of two per mouse) with adenoviral vector expressing red fluorescent protein (RFP). The results of a representative experiment are shown in <figref idrefs="f0006">Figure 4</figref>. Almost complete lack of growth of tumors injected with (pCD515-CMV-hTLR5-EF1-502s) was accompanied with reduced growth of the uninjected tumor within the same animal as compared with the tumors in control animals injected with RFP-expressing adenovirus. This result indicates (i) powerful in-cis and (ii) visible in-trans effect of pCD515-CMV-hTLR5-EF1-502s indicative of recruitment of both innate (cis effect) and adaptive (trans effect) immune response. Neither of the other control viruses listed in Table 1 (i.e., AD5 (control) and Ad5 (TLR5)) injected alone had growth suppressive effects on tumors.</p><p id="p0080" num="0080">Thus, enforced ectopic expression of TLR5 makes tumor cell types, which originally were TLR5 deficient, highly responsive to TLR5 stimulation resulting in breaking tumor immuno-tolerance, powerful attraction of innate immune response that promotes effective development of adaptive immune response with subsequent general antitumor effect.</p></description><claims mxw-id="PCLM56983679" lang="DE" load-source="patent-office"><!-- EPO <DP n="24"> --><claim id="c-de-01-0001" num="0001"><claim-text>Vektor umfassend eine erste und eine zweite Nukleinsäure, wobei die erste Nukleinsäure einen Toll-like-Rezeptor kodiert, und die zweite Nukleinsäure einen Toll-like-Rezeptor-Agonisten kodiert, ausgewählt aus der Gruppe bestehend aus Hitzeschockproteinen, High-Mobility Group-Box 1, Fibrinogen, Fibronektin, RSV-Fusionsprotein, Maus-Mammatumorvirus-Hüllproteinen, Flagellin und Profilin.</claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Vektor nach Anspruch 1, wobei der Toll-like-Rezeptor-Agonist Flagellin ist.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Vektor nach Anspruch 1, wobei der Vektor ein Expressionsvektor ist.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Vektor nach Anspruch 3, wobei der Vektor ein Mamma-Expressionsvektor ist.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Vektor nach Anspruch 3, wobei der Vektor aus einem Adenovirus, einem Lentivirus oder einem Liposom exprimiert ist.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Vektor nach Anspruch 1, wobei die erste Nukleinsäure eine abgesonderte Form eines Toll-like-Rezeptors ist.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Vektor nach Anspruch 2, wobei das Flagellin eine abgesonderte Form von Flagellin ist.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Vektor nach Anspruch 1, wobei der Toll-like-Rezeptor-Agonist TLR-5 ist.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Vektor nach einem der Ansprüche 1 bis 8 zur Verwendung als ein Arzneimittel.<!-- EPO <DP n="25"> --></claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Mittel zur Verwendung bei der Krebsbehandlung in einem behandlungsbedürftigen Säugetier, wobei das Mittel den Vektor nach einem der Ansprüche 1 bis 8 umfasst.</claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>Mittel zur Verwendung nach Anspruch 10, wobei der Krebs ein Tumor ist.</claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>Mittel zur Verwendung nach Anspruch 11, wobei der Tumor aus der Gruppe bestehend aus Prostata, Brust, Kolon, Ösophagus, Magen, Lunge, Pankreas, Niere, Schilddrüse, Eierstöcken, Hals, Zervix, Sarkomen, Melanomen, Leukämien und Lymphomen abgeleitet ist.</claim-text></claim><claim id="c-de-01-0013" num="0013"><claim-text>Mittel zur Verwendung bei der Behandlung einer Infektion in einem behandlungsbedürftigen Säugetier, wobei das Mittel den Vektor nach einem der Ansprüche 1 bis 8 umfasst.</claim-text></claim><claim id="c-de-01-0014" num="0014"><claim-text>Mittel zur Verwendung nach Anspruch 13, wobei die Infektion aus einem Organismus ist, welcher aus der Gruppe bestehend aus einem Virus, einem Bakterium, einem Protozoon-Parasiten und einem Pilz ausgewählt ist.</claim-text></claim></claims><claims mxw-id="PCLM56983680" lang="EN" load-source="patent-office"><!-- EPO <DP n="23"> --><claim id="c-en-01-0001" num="0001"><claim-text>A vector comprising a first and second nucleic acid, wherein the first nucleic acid encodes a toll-like receptor and the second nucleic acid encodes a toll-like receptor agonist selected from the group consisting of heat shock proteins, high mobility group box 1, fibrinogen, fibronectin, RSV fusion protein, mouse mammary tumor virus envelope proteins, flagellin, and profilin.</claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>The vector of claim 1, wherein the toll-like receptor agonist is flagellin.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>The vector of claim 1, wherein the vector is an expression vector.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>The vector of claim 3, wherein the vector is a mammalian expression vector.</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>The vector of claim 3, wherein the vector is expressed from an adenovirus, a lentivirus or a liposome.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>The vector of claim 1, wherein the first nucleic acid is a secreted form of a toll-like receptor.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>The vector of claim 2 wherein the flagellin is a secreted form of flagellin.</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>The vector of claim 1, wherein the toll-like receptor is TLR-5.</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>The vector of any of claims 1 to 8 for use as a medicament.</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>An agent for use in treating cancer in a mammal in need thereof, wherein the agent comprises the vector of any one of claims 1-8.</claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>The agent for use of claim 10, wherein the cancer is a tumor.</claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>The agent for use of claim 11, wherein the tumor is derived from the group consisting of prostate, breast, colon, esophagus, stomach, lung, pancreatic, renal, thyroid, ovaries, throat, cervix, sarcomas, melenomas, leukemias, and lymphomas.</claim-text></claim><claim id="c-en-01-0013" num="0013"><claim-text>An agent for use in treating an infection in a mammal in need thereof, wherein the agent comprises the vector of any one of claims 1-8.</claim-text></claim><claim id="c-en-01-0014" num="0014"><claim-text>The agent for use of claim 13, wherein the infection is by an organism selected from the group consisting of a virus, a bacterium, a protozoan parasites, and a fungus.</claim-text></claim></claims><claims mxw-id="PCLM56983681" lang="FR" load-source="patent-office"><!-- EPO <DP n="26"> --><claim id="c-fr-01-0001" num="0001"><claim-text>Vecteur comprenant un premier et un deuxième acide nucléique, le premier acide nucléique codant pour un récepteur de type Toll et le deuxième acide nucléique codant pour un agoniste du récepteur de type Toll sélectionné du groupe composé des protéines de choc thermique, du groupe box 1 à haute mobilité, du fibrinogène, de la fibronectine, de la protéine de fusion du RSV, des protéines d'enveloppe du virus de la tumeur mammaire de la souris, de la flagelline et de la profiline.</claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Vecteur selon la revendication 1, dans lequel l'agoniste du récepteur de type Toll est la flagelline.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Vecteur selon la revendication 1, dans lequel le vecteur est un vecteur d'expression.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Vecteur selon la revendication 3, dans lequel le vecteur est un vecteur d'expression de mammifère.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Vecteur selon la revendication 3, dans lequel le vecteur est exprimé à partir d'un adénovirus, d'un lentivirus ou d'un liposome.</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Vecteur selon la revendication 1, dans lequel le premier acide nucléique est une forme sécrétée d'un récepteur de type Toll.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>Vecteur selon la revendication 2, dans lequel la flagelline est une forme sécrétée de la flagelline.</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>Vecteur selon la revendication 1, dans lequel le récepteur de type Toll est TLR-5.<!-- EPO <DP n="27"> --></claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>Vecteur selon l'une quelconque des revendications 1 à 8 pour l'utilisation en tant qu'un médicament.</claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>Agent pour l'utilisation dans le traitement du cancer chez un mammifère en ayant besoin, dans lequel l'agent comprend le vecteur selon l'une quelconque des revendications 1 à 8.</claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>Agent pour l'utilisation selon la revendication 10, dans lequel le cancer est une tumeur.</claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>Agent pour l'utilisation selon la revendication 11, la tumeur provient du groupe composé de la prostate, du sein, du côlon, de l'oesophage, de l'estomac, du poumon, du pancréas, du rein, de la thyroïde, des ovaires, de la gorge, du col utérin, des sarcomes, des mélanomes, des leucémies et des lymphomes.</claim-text></claim><claim id="c-fr-01-0013" num="0013"><claim-text>Agent pour l'utilisation dans le traitement d'une infection chez un mammifère en ayant besoin, dans lequel l'agent comprend le vecteur selon l'une quelconque des revendications 1 à 8.</claim-text></claim><claim id="c-fr-01-0014" num="0014"><claim-text>Agent pour l'utilisation selon la revendication 13, dans lequel l'infection est causée par un organisme sélectionné du groupe consistant en un virus, une bactérie, un parasite protozoaire et un champignon.</claim-text></claim></claims><drawings mxw-id="PDW16671622" load-source="patent-office"><!-- EPO <DP n="28"> --><figure id="f0001" num="1A"><img id="if0001" file="imgf0001.tif" wi="165" he="204" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="29"> --><figure id="f0002" num="1B"><img id="if0002" file="imgf0002.tif" wi="165" he="175" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="30"> --><figure id="f0003" num="1C"><img id="if0003" file="imgf0003.tif" wi="165" he="179" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="31"> --><figure id="f0004" num="2"><img id="if0004" file="imgf0004.tif" wi="136" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="32"> --><figure id="f0005" num="3"><img id="if0005" file="imgf0005.tif" wi="165" he="206" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="33"> --><figure id="f0006" num="4"><img id="if0006" file="imgf0006.tif" wi="95" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="34"> --><figure id="f0007" num="5"><img id="if0007" file="imgf0007.tif" wi="161" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="35"> --><figure id="f0008" num="6"><img id="if0008" file="imgf0008.tif" wi="161" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="36"> --><figure id="f0009" num="7"><img id="if0009" file="imgf0009.tif" wi="136" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="37"> --><figure id="f0010" num="7"><img id="if0010" file="imgf0010.tif" wi="133" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="38"> --><figure id="f0011" num="7"><img id="if0011" file="imgf0011.tif" wi="133" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="39"> --><figure id="f0012" num="7"><img id="if0012" file="imgf0012.tif" wi="133" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="40"> --><figure id="f0013" num="7"><img id="if0013" file="imgf0013.tif" wi="133" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="41"> --><figure id="f0014" num="7"><img id="if0014" file="imgf0014.tif" wi="133" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="42"> --><figure id="f0015" num="7"><img id="if0015" file="imgf0015.tif" wi="133" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="43"> --><figure id="f0016" num="7"><img id="if0016" file="imgf0016.tif" wi="133" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="44"> --><figure id="f0017" num="7"><img id="if0017" file="imgf0017.tif" wi="133" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="45"> --><figure id="f0018" num="7"><img id="if0018" file="imgf0018.tif" wi="133" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="46"> --><figure id="f0019" num="7suie"><img id="if0019" file="imgf0019.tif" wi="144" he="99" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="47"> --><figure id="f0020" num="8A"><img id="if0020" file="imgf0020.tif" wi="165" he="189" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="48"> --><figure id="f0021" num="8A"><img id="if0021" file="imgf0021.tif" wi="165" he="105" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="49"> --><figure id="f0022" num="8B"><img id="if0022" file="imgf0022.tif" wi="165" he="137" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="50"> --><figure id="f0023" num="9"><img id="if0023" file="imgf0023.tif" wi="103" he="209" img-content="drawing" img-format="tif"/></figure></drawings><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
